|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.120 USD | -.--% |
|
-.--% | -22.76% |
| Jul. 13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| Jul. 10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
| Market Cap | 56.17M 64.89M 52.36M 48.18M 90.91M 6.17B 91.94M 616M 241M 3.09B 244M 238M 10.23B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 56.17M 64.89M 52.36M 48.18M 90.91M 6.17B 91.94M 616M 241M 3.09B 244M 238M 10.23B | EV / Sales 2026 * |
46.8x | EV / Sales 2027 * | 43.2x |
| Free-Float |
63.24% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: AB Science
| 6 months | -22.76% | ||
| Current year | -22.76% |
| Current year | 1.12 |  | 1.37 |
| 1 year | 1.12 | | 1.45 |
| 3 years | 0 | | 3.84 |
| 5 years | 0 | | 17.1 |
| 10 years | 0 | | 26.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2026-07-06 | |
Laurent Guy
DFI | Director of Finance/CFO | - | 2009-11-19 |
| Chief Tech/Sci/R&D Officer | - | 2018-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CHM | Chairman | - | 2001-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 2011-09-19 |
| Director/Board Member | 64 | 2021-06-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 59.71M | |
| +0.26% | -2.65% | +60.69% | +22.22% | 316B | |
| -0.92% | +0.52% | +34.01% | -10.27% | 73.28B | |
| +0.43% | +0.17% | +39.34% | +97.10% | 9.87B | |
| +0.10% | -7.59% | -4.29% | -6.23% | 8.15B | |
| +2.76% | +3.14% | -14.67% | -14.85% | 4.38B | |
| +0.40% | +6.22% | -33.30% | +7.29% | 3.91B | |
| +2.46% | +2.51% | -14.87% | +21.19% | 3.62B | |
| +8.46% | -1.72% | +26.61% | +45.77% | 2.51B | |
| -0.19% | +6.42% | -2.77% | -3.33% | 2.24B | |
| Average | +1.38% | -0.50% | +10.08% | +17.65% | 47.12B | |
| Weighted average by Cap. | +0.15% | -1.99% | +51.51% | +17.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.2M 1.39M 1.12M 1.03M 1.94M 132M 1.96M 13.15M 5.16M 66.08M 5.21M 5.09M 219M | 1.3M 1.5M 1.21M 1.12M 2.1M 143M 2.13M 14.25M 5.59M 71.59M 5.64M 5.52M 237M |
| Net income | - | - |
| Net Debt | - | - |
Employees
31
Sector
Pharmaceuticals
Calendar
Sep. 30
Earnings release - Q2 2026
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AB Stock
- ABSCF Stock
Select your edition
All financial news and data tailored to specific country editions
